DONATE

Free Support Line: 833-275-4222

Return to Map

Virginia Bladder Cancer Resources

Return to Map

Virginia Department of Health
http://vdh.virginia.gov/

Contact Your State Elected Representative

Bladder Cancer Cases in Virginia at a Glance

  • 1,970

    New State Cases
     

  • 84,870

    New National
    Cases

  • 65,080

    National Cases in Men

  • 19,790

    National Cases in Women

  • 17,420

    National Deaths
     

NCI-Designated Cancer Centers and NCCN Member Institutions

The National Cancer Institute, (NCI) has recognized Cancer Centers for delivering cutting-edge cancer treatments to patients in communities across the United States. There are 71 NCI-Designated Cancer Centers, located in 36 states and the District of Columbia, that are funded by NCI to deliver cutting-edge cancer treatments to patients. Most of the NCI-Designated Cancer Centers are affiliated with university medical centers, although several are freestanding institutions that engage only in cancer research.

The National Comprehensive Cancer Centers (NCCN) are a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives.

Massey Cancer Center

Richmond, VA
804-828-0450
University of Virginia Cancer Center

Charlottesville, VA
434-924-3627

Veterans Administration Hospitals

Hampton VA Medical Center
Hunter Holmes McGuire VA Medical Center
Salem VA Medical Center

Bladder Cancer Clinical Trials in Virginia

Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
See more clinical trials

Richmond Walk to End Bladder Cancer

Spring 2024

Register to walk

Read Our Stories